IO Biotech Other Current Assets Over Time
| IOBT Stock | USD 0.75 0.04 5.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out IO Biotech Performance and IO Biotech Correlation. IOBT |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IO Biotech. If investors know IOBT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IO Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Return On Assets (0.51) | Return On Equity (0.88) |
The market value of IO Biotech is measured differently than its book value, which is the value of IOBT that is recorded on the company's balance sheet. Investors also form their own opinion of IO Biotech's value that differs from its market value or its book value, called intrinsic value, which is IO Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IO Biotech's market value can be influenced by many factors that don't directly affect IO Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IO Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if IO Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IO Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Assets Analysis
Compare IO Biotech and related stocks such as Pmv Pharmaceuticals, Eliem Therapeutics, and MediciNova Other Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMVP | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 607 K | 6.7 M | 4.1 M | 6 M | 4.4 M | 4 M |
| MNOV | 108.4 K | 614.5 K | 411.6 K | 1.7 M | 463.5 K | 649.5 K | 585.8 K | 336.6 K | 444.9 K | 511.9 K | 680.2 K | 578 K | 499.4 K | 174.9 K | 166.2 K |
| PHVS | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 47.5 K | 1.8 M | 1.5 M | 4.6 M | 5.6 M | 5.9 M |
| PEPG | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 134 K | 2.3 M | 4.3 M | 2.3 M | 2 M |
| STTK | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 3.4 M | 20.4 M | 38.9 M | 23.3 M | 12.6 M | 19 M |
| CSBR | 20 K | 205 K | 358 K | 383 K | 346 K | 443 K | 300 K | 287 K | 308 K | 385 K | 957 K | 2.3 M | 1.3 M | 1.5 M | 1.6 M |
| IPSC | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.4 M | 124 K | 124 K | 124 K | 3 M | 5 M | 3.4 M | 4.3 M | 4 M |
| GPCR | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 1.9 M | 2.2 M | 6.3 M | 3.1 M |
| ERAS | 752 K | 752 K | 752 K | 752 K | 752 K | 752 K | 752 K | 752 K | 752 K | 752 K | 2.6 M | 11.1 M | 8.9 M | 8.3 M | 7 M |
| LYRA | 872 K | 872 K | 872 K | 872 K | 872 K | 872 K | 872 K | 872 K | 872 K | 311 K | 2.6 M | 4.3 M | 2.9 M | 2.1 M | 2.4 M |
| GLUE | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 1.8 M | 5.2 M | 5.4 M | 3.3 M | 3.6 M |
| NAMS | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 7.5 M | 8.2 M | 4.5 M | 6 M |
| IVA | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.2 M | (1.0) | 6.2 M | 3.1 K | (1000) | (1000) | 25.9 M | 23.9 M | 9.6 M | 4.7 M | 7.3 M |
| CGEM | 10 K | 10 K | 10 K | 5 K | 1000 | 387 K | 387 K | 387 K | 387 K | 1.5 M | 4.1 M | 12.2 M | 7.2 M | 13.1 M | 13.8 M |
| CMPX | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 935 K | 3.1 M | 2.6 M | 8.2 M | 1.4 M | 1.3 M |
| DSGN | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 132 K | 1.3 M | 8.3 M | 1.4 M | 2.4 M |
| HOWL | 167 K | 167 K | 167 K | 167 K | 167 K | 167 K | 167 K | 167 K | 167 K | 167 K | 688 K | 7.1 M | 4 M | 2.7 M | 3.2 M |
| IKNA | 582 K | 582 K | 582 K | 582 K | 582 K | 582 K | 582 K | 582 K | 582 K | 1.3 M | 3.5 M | 4.3 M | 3.1 M | 3.2 M | 2.9 M |
| STOK | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 548 K | 3.3 M | 6.6 M | 9.3 M | 13.9 M | 13.9 M | 7.5 M |
IO Biotech and related stocks such as Pmv Pharmaceuticals, Eliem Therapeutics, and MediciNova Other Current Assets description
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.My Equities
My Current Equities and Potential Positions
| IO Biotech | IOBT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Denmark |
| Exchange | NASDAQ Exchange |
USD 0.75
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.